Chimerix Inc banner

Chimerix Inc
NASDAQ:CMRX

Watchlist Manager
Chimerix Inc Logo
Chimerix Inc
NASDAQ:CMRX
Watchlist
Price: 8.54 USD -0.12% Market Closed
Market Cap: $801.1m

Chimerix Inc
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Chimerix Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Chimerix Inc
NASDAQ:CMRX
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Inventory
$5B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Inventory
$1.8B
CAGR 3-Years
6%
CAGR 5-Years
1%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Inventory
$6.2B
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
10%
Exact Sciences Corp
NASDAQ:EXAS
Inventory
$166.2m
CAGR 3-Years
12%
CAGR 5-Years
12%
CAGR 10-Years
38%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Inventory
$1.7B
CAGR 3-Years
54%
CAGR 5-Years
43%
CAGR 10-Years
40%
No Stocks Found

Chimerix Inc
Glance View

Market Cap
801.1m USD
Industry
Biotechnology

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 87 full-time employees. The company went IPO on 2013-04-11. The firm is focused on discovering, developing and commercializing medicines that address unmet medical needs. The firm offers TEMBEXA (brincidofovir) is an antiviral for the treatment of smallpox in all age groups, including infants, and for patients who have difficulty swallowing. The firm's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. The Company’s DSTAT is a glycosaminoglycan derivative of heparin, which is a treatment for hematologic malignancies, including newly diagnosed acute myeloid leukemia (AML) in combination with standard chemotherapy.

CMRX Intrinsic Value
1.45 USD
Overvaluation 83%
Intrinsic Value
Price

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett